| Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer (NCT05364645) | SWOG Cancer Research Network | 2022-07-25 |
| Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors (NCT05334329) | University of California, Irvine | 2022-07-20 |
| Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial (NCT05339022) | Ohio State University Comprehensive Cancer Center | 2022-04-14 |
| A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer (NCT05215769) | Ohio State University Comprehensive Cancer Center | 2022-03-30 |
| Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (NCT05096663) | SWOG Cancer Research Network | 2022-03-15 |
| Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer (NCT05166616) | City of Hope Medical Center | 2022-03-07 |
| Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer (NCT05017025) | M.D. Anderson Cancer Center | 2022-02-17 |
| Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer (NCT04919382) | Dwight Owen | 2022-01-26 |
| Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (NCT04780568) | Ohio State University Comprehensive Cancer Center | 2022-01-18 |
| All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (NCT04919369) | Dwight Owen | 2021-10-18 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (NCT04940299) | M.D. Anderson Cancer Center | 2021-09-23 |
| Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer (NCT04971187) | M.D. Anderson Cancer Center | 2021-06-30 |
| Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer (NCT05045404) | M.D. Anderson Cancer Center | 2021-06-16 |
| A Biobehavioral/Cognitive Treatment for Stress, Depression, and Anxiety in Patients With Stage IV Lung Cancer (NCT05342571) | Ohio State University Comprehensive Cancer Center | 2021-06-01 |
| Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity (NCT04954885) | Ohio State University Comprehensive Cancer Center | 2021-05-18 |
| Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (NCT04625647) | SWOG Cancer Research Network | 2021-04-16 |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (NCT04902040) | M.D. Anderson Cancer Center | 2021-04-14 |
| Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies (NCT04785287) | M.D. Anderson Cancer Center | 2021-03-29 |
| Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer (NCT04837716) | M.D. Anderson Cancer Center | 2021-03-18 |
| A Nurse-Led Intervention for Fear of Progression in Advanced Cancer (NCT04819997) | City of Hope Medical Center | 2021-03-08 |
| MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer (NCT04762199) | Emory University | 2021-02-24 |
| Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (NCT03819296) | M.D. Anderson Cancer Center | 2021-02-21 |
| Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study (NCT05022394) | M.D. Anderson Cancer Center | 2021-02-18 |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases (NCT04752267) | University of Southern California | 2021-02-15 |
| Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer (NCT04751747) | Rutgers, The State University of New Jersey | 2021-02-11 |
| Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer (NCT04285671) | Jonsson Comprehensive Cancer Center | 2021-01-29 |
| Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases (NCT04789668) | M.D. Anderson Cancer Center | 2021-01-15 |
| Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial (NCT04728230) | M.D. Anderson Cancer Center | 2021-01-05 |
| Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer (NCT04533451) | Alliance for Clinical Trials in Oncology | 2020-11-16 |
| Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer (NCT04250545) | National Cancer Institute (NCI) | 2020-10-26 |
| Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer (NCT04396535) | Mayo Clinic | 2020-10-23 |
| Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) (NCT04267913) | SWOG Cancer Research Network | 2020-09-05 |
| Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis (NCT04516070) | M.D. Anderson Cancer Center | 2020-08-28 |
| Family Caregivers in Underserved Populations Providing Complex Cancer Care (NCT05213078) | City of Hope Medical Center | 2020-07-15 |
| Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer (NCT04479306) | M.D. Anderson Cancer Center | 2020-06-18 |
| Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade (NCT04340882) | Emory University | 2020-06-05 |
| Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy (NCT03965689) | National Cancer Institute (NCI) | 2020-04-16 |
| Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) (NCT04268550) | SWOG Cancer Research Network | 2020-04-08 |
| Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer (NCT04262869) | Emory University | 2020-03-27 |
| Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC (NCT04227028) | City of Hope Medical Center | 2020-03-09 |
| Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) (NCT04173507) | SWOG Cancer Research Network | 2020-02-14 |
| Resiliency Among Older Adults Receiving Lung Cancer Treatment (NCT04229381) | Ohio State University Comprehensive Cancer Center | 2020-01-22 |
| Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer (NCT04073745) | Roswell Park Cancer Institute | 2019-12-04 |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (NCT03987555) | Wake Forest University Health Sciences | 2019-11-11 |
| [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy (NCT04186988) | University of California, Davis | 2019-11-05 |
| Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study (NCT04430725) | M.D. Anderson Cancer Center | 2019-08-07 |
| Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (NCT03737994) | National Cancer Institute (NCI) | 2019-07-25 |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (NCT03707574) | National Cancer Institute (NCI) | 2019-07-16 |
| CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer (NCT03546361) | Jonsson Comprehensive Cancer Center | 2019-07-08 |
| Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer (NCT03995667) | OHSU Knight Cancer Institute | 2019-06-11 |
| Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) (NCT03971474) | SWOG Cancer Research Network | 2019-05-28 |
| Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (NCT03845296) | SWOG Cancer Research Network | 2019-04-16 |
| Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer (NCT03581487) | M.D. Anderson Cancer Center | 2019-04-01 |
| Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers (NCT03902535) | City of Hope Medical Center | 2019-03-08 |
| Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (NCT03830918) | Jonsson Comprehensive Cancer Center | 2019-03-06 |
| Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer (NCT03944265) | Thomas Jefferson University | 2019-02-08 |
| Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers (NCT03948100) | M.D. Anderson Cancer Center | 2018-12-20 |
| Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (NCT03707938) | M.D. Anderson Cancer Center | 2018-12-18 |
| Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers (NCT04662645) | Ohio State University Comprehensive Cancer Center | 2018-12-12 |
| Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer (NCT03637816) | M.D. Anderson Cancer Center | 2018-11-27 |
| Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment (NCT03731585) | M.D. Anderson Cancer Center | 2018-11-15 |
| Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer (NCT03662074) | Wake Forest University Health Sciences | 2018-11-07 |
| Bronchoscopic Laser Ablation of Peripheral Lung Tumors (NCT03707925) | M.D. Anderson Cancer Center | 2018-09-18 |
| Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (NCT03590054) | Rahul Aggarwal | 2018-08-20 |
| Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery (NCT03582124) | Stanford University | 2018-07-19 |
| Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced (NCT03225664) | M.D. Anderson Cancer Center | 2018-02-03 |
| Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study (NCT03410043) | M.D. Anderson Cancer Center | 2018-01-17 |
| Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors (NCT02589522) | National Cancer Institute (NCI) | 2017-05-22 |
| CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer (NCT02955290) | Roswell Park Cancer Institute | 2016-12-22 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |
| 4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis (NCT00862680) | M.D. Anderson Cancer Center | 2009-03-12 |